Exact (EXAS) Highlighted As Today's Perilous Reversal Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Exact ( EXAS) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Exact as such a stock due to the following factors:

  • EXAS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $63.9 million.
  • EXAS has traded 299,049 shares today.
  • EXAS is down 3.1% today.
  • EXAS was up 6.4% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in EXAS with the Ticky from Trade-Ideas. See the FREE profile for EXAS NOW at Trade-Ideas

More details on EXAS:

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. Currently there are 5 analysts that rate Exact a buy, 1 analyst rates it a sell, and 2 rate it a hold.

The average volume for Exact has been 1.4 million shares per day over the past 30 days. Exact has a market cap of $1.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.41 and a short float of 35.1% with 7.46 days to cover. Shares are up 66.1% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Exact Sciences Stock Falls on Secondary Stock Sale

Exact Sciences: Cramer's Top Takeaways

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)